November 2, 2023
This is NOT going to end well.
Looking over the results released by Tandem yesterday and reading through the earnings call transcript a few things stood out-
1. Tandem is almost like a teenager who gets caught in lie and then comes up with multiple explanations to explain away this lie.
2. The company is also trying to jump on the GLP-1 bandwagon and using clinical data to back up their assertion that increasing GLP-1 usage will help Tandem – it won’t but we’ll have more on that in a minute.
3. It’s now crystal clear that Tandem is on the same path . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
